Posted on October 21, 2018 by Sitemaster
New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, debulking, deprivation, docetaxel, metastasis, primary, radiation, therapy, tumor | 7 Comments »
Posted on October 1, 2018 by Sitemaster
The term “debulking” denotes the radical treatment (via prostatectomy or radiation therapy) of the cancerous prostate — lmost always in newly diagnosed patients — after distant metastases have been discovered. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: debulking, primary, prostatectomy, radiation, therapy, trial, tumor | 24 Comments »
Posted on September 28, 2018 by Sitemaster
A newly published study from a group of researchers at the Garvan Institute in Scotland has again confirmed the apparent genetic risk for some forms of prostate cancer among men of African ethnic origin. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: African, burden, genetics, risk, tumor | 3 Comments »
Posted on September 4, 2018 by Sitemaster
Over the years, a good deal of data has been accumulated suggesting that local treatment (ablation) of the primary tumor may have benefit in the long-term outcomes of men with metastatic prostate cancer at time of initial diagnosis. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ablation, metastatic, newly diagnosed, primary, tumor | 9 Comments »
Posted on March 6, 2018 by Sitemaster
We have previously had no really accurate data on a very important question: Does local treatment of men initially diagnosed with advanced prostate cancer impact their long-term survival and mortality rates? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: advanced, debulking, outcome, survival, tumor | 4 Comments »
Posted on March 6, 2018 by Sitemaster
The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, circulating, ctDNA, DNA, liquid, review, test, tumor | 2 Comments »
Posted on January 11, 2018 by Sitemaster
A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: cell, ciculating, clinical, count, CTC, endpoint, trial, tumor | 4 Comments »
Posted on November 14, 2017 by Sitemaster
A new article in the upcoming December issue of the Journal of Urology has shown that, for men with higher risk prostate cancers, tumors found in the transition zone of the prostate are less “risky” than the same types of cancer when they occur in the peripheral and central zones. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: location, outcome, risk, surgery, tumor, zone | 8 Comments »
Posted on July 24, 2017 by Sitemaster
A newly published study in Clinical Cancer Research has implied the potential development of a completely new and much more accurate way to be able to identify risk for metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: blood, cell, circulating, count, CTC, megakaryocyte, PSA, tumor | 1 Comment »
Posted on June 29, 2017 by Sitemaster
A recent article (in German in Der Urologe) has discussed the early use of PSMA-radio-guided surgery (PSMA-RGS) for targeted resection of localized prostate cancer recurrence. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: identification, PSMA, radio-guidance, recurrence, surgery, tumor | 1 Comment »
Posted on November 7, 2016 by Sitemaster
According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: cell, circulating, CTC, metastasis, progression, risk, tumor | 3 Comments »
Posted on March 22, 2016 by Sitemaster
In another breaking story from the UK, a company called Angle PLC has announced that its Parsortix diagnostic system can potentially be used to identify men with prostate cancer using a simple blood sample and testing for the presence of circulating tumor cells (CTCs). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Angle, cell, circulating, CTC, Diagnosis, Parsortix, risk, tumor | Leave a comment »
Posted on March 1, 2016 by Sitemaster
There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be “tailor-made” for individualized, precision cancer therapy. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: genetic, genomic, metastatic, outcome, profile, Treatment, tumor | 1 Comment »
Posted on January 7, 2016 by Sitemaster
A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, cell, circulating, CTC, liquid, selection, Treatment, tumor | Leave a comment »
Posted on November 11, 2015 by Sitemaster
A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, cell, circulating, CTC, expression, liquid, PTEN, tumor | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 